Open an account

Canton Strategic Holdings

CNTN · NASDAQ

$1.73+$0.04 (+2.37%)TodayMarket closed ·
Prev close $1.69

About CNTN

Canton Strategic Holdings, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 12 full-time employees. The company went IPO on 2022-01-12. In addition to driving value through activities on the Canton Network, the Company operates a Super Validator, ensuring safe and secure transactions across the Network. The firm also operates a clinical-stage biotech research and development arm. Its lead clinical asset, GV104, is being developed for a specific indication via a 505(b)2 pathway for respiratory and/or nervous system depression in military personnel and chemical incident responders who may encounter high-potency opioids. The expanded pipeline includes other indications for GV104 and GV023, a new approach to autoimmune diseases, as well as an early-stage multispecific biologic platform.

Employees
12
Headquarters
Bridgewater, New Jersey
Listed
Jan 12, 2022
Sector
Health Care
Industry
Biotechnology
Website
cantonstrategic.com

CNTN key statistics

Market cap
137.85M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
787.45K
Volume
661.05K
Open price
$1.68
High today
$1.78
Low today
$1.67
52 Week high
$6.89
52 Week low
$1.66

Canton Strategic Holdings (CNTN) at a glance

Canton Strategic Holdings (CNTN) last traded at $1.73, with a market cap of 137.85M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.67 and $1.78. The current price is 3.6% above the day's low and 2.8% below its high.

Volume so far is 661.05K shares, in line with the average of 787.45K shares a day.

Over the past year Canton Strategic Holdings has ranged from $1.66 to $6.89, and now sits 1% of the way up that range.

Canton Strategic Holdings met or beat analyst EPS estimates in 2 of the last 4 quarters. In Q4 FY23 it reported -$10.69 per share against an estimate of -$19.13.

CNTN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 4 quarters, by 23.0% on average.

  1. Q1 FY23: reported -$86.25 per share against an estimate of -$42.08
  2. Q2 FY23: reported -$60.00 per share against an estimate of -$61.20
  3. Q3 FY23: reported -$41.25 per share against an estimate of -$22.95
  4. Q4 FY23: reported -$10.69 per share against an estimate of -$19.13

CNTN news

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Delivers Third Quarter Canton Network Ecosystem Update

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results

  • Press releasePRNewswire

    Three New Directors Elected to the Board of Canton Strategic Holdings, Inc.

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Announces Sale of Gravitas Life Sciences, LLC

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Delivers Second Quarter Canton Network Ecosystem Update

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000® and Russell 2000®

  • Press releasePRNewswire

    Canton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program

Similar companies

Companies in the same industry as Canton Strategic Holdings

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.